Literature DB >> 1901492

Magnetic resonance imaging of central nervous system lesions in patients with lupus erythematosus. Correlation with clinical remission and antineurofilament and anticardiolipin antibody titers.

C L Bell1, C Partington, M Robbins, F Graziano, P Turski, S Kornguth.   

Abstract

Clinical, magnetic resonance imaging (MRI), and serologic studies were performed on 11 patients with diffuse central nervous system (CNS) systemic lupus erythematosus and 8 patients with focal CNS lupus. MRI of patients with diffuse clinical disease showed symmetrically distributed areas of increased signal intensity in the subcortical white matter; these resolved after treatment with high-dose methylprednisolone. These patients' sera contained elevated levels of antineurofilament antibodies. Patients with focal CNS lupus had areas of increased signal intensity and atrophic changes in regions corresponding to the major cerebral vessels. These MRI abnormalities did not improve after treatment with high-dose steroids. The sera of patients with focal CNS lupus had elevated levels of cardiolipin and lupus anticoagulant but normal levels of antineurofilament antibody. Our findings suggest that results of a combined clinical, MRI, and serologic evaluation of patients with CNS lupus may predict the response of patients to high-dose steroid therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901492     DOI: 10.1002/art.1780340408

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  18 in total

Review 1.  Neuroimaging techniques in the diagnostic work-up of patients with the antiphospholipid syndrome.

Authors:  M Rovaris; C Pedroso; M Filippi
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 2.  Neuropsychiatric lupus.

Authors:  J G Hanly
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

3.  Sensitivity of quantitative (1)H magnetic resonance spectroscopy of the brain in detecting early neuronal damage in systemic lupus erythematosus.

Authors:  J S Axford; F A Howe; C Heron; J R Griffiths
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

4.  Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study.

Authors:  M Rovaris; B Viti; G Ciboddo; S Gerevini; R Capra; G Iannucci; G Comi; M Filippi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

5.  Subdural fluid collections: an unusual manifestation of CNS disease in a connective tissue disorder.

Authors:  D J Shaskey; J F Mijer; H J Williams; A D Sawitzke
Journal:  Clin Rheumatol       Date:  1995-01       Impact factor: 2.980

Review 6.  Current concepts of neuropsychiatric systemic lupus erythematosus (NP-SLE).

Authors:  R A Asherson; S D Denburg; J A Denburg; R M Carbotte; N Futrell
Journal:  Postgrad Med J       Date:  1993-08       Impact factor: 2.401

7.  Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum.

Authors:  K H Sun; W T Liu; C Y Tsai; T S Liao; W M Lin; C L Yu
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

8.  MRI changes in the central nervous system in a child with lupus erythematosus.

Authors:  M A Gieron; S Khoromi; A Campos
Journal:  Pediatr Radiol       Date:  1995

9.  Abnormalities of magnetic resonance imaging of the central nervous system in patients with systemic lupus erythematosus correlate with disease severity.

Authors:  A Cauli; C Montaldo; M T Peltz; P Nurchis; G Sanna; P Garau; R Pala; G Passiu; A Mathieu
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

10.  Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus.

Authors:  Michelle Petri; Mohammad Naqibuddin; Kathryn A Carson; Daniel J Wallace; Michael H Weisman; Stephen L Holliday; Margaret Sampedro; Shalini Narayana; Peter T Fox; Crystal Franklin; Patricia A Padilla; Robin L Brey
Journal:  J Rheumatol       Date:  2008-09-15       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.